1962: Ranjit Singh and Gurbux Singh incorporate Ranbaxy to market pharmaceuticals in Amritsar, India, and borrow funding from moneylender Bhai Mohan Singh. 1966: Bhai Mohan Singh takes over Ranbaxy in lieu of repayment of the loan. 1967: Son Dr. Parvinder Singh joins the company, which begins producing generic drugs. 1969: Calmpose, a Valium generic, is launched, becoming the company's first success. 1973: Ranbaxy goes public and builds a new API chemicals facility in Mohali. 1977: The company begins production in Lagos, Nigeria through a joint venture. 1983: The company opens a dosage plant in Dewas. 1987: The company builds a state-of-the-art API facility in Toansa in preparation for entry into the U.S. market. 1988: The Toansa facility receives FDA approval. 1992: The company launches a joint marketing agreement with Eli Lilly. 1993: A joint venture is launched in China; a new research-driven NCE and NDDS strategy is launched. 1994: The company opens a new research and development facility in Gurgaon, India. 1995: The company acquires Ohm Laboratories in the United States and builds a new FDA-approved production facility. 1998: Ranbaxy begins marketing its own branded drugs in the United States; the company launches clinical trials on the first in-house developed molecule. 2000: Ranbaxy acquires Basics, Bayer's generics business in Germany; the company enters Brazil. 2003: Ranbaxy successfully completes the first NCE phase I clinical trial; the company acquires RPG (Aventis) in France, becoming the leading generics manufacturer for that market. 2005: The company launches a new $100 million production facility in Brazil.